The global antipruritic market size is projected to surpass a valuation of USD 16.2 billion by 2034. Our healthcare analysts opine that antipruritic manufacturers can expect a CAGR of 4.2% through 2034, with a current valuation of USD 10.9 billion in 2024.
| Attributes | Market Insights |
|---|---|
| Market Value 2023 | USD 10.5 billion |
| Market Value 2024 | USD 10.9 billion |
| Market Value 2034 | USD 16.2 billion |
| CAGR 2024 to 2034 | 4.2% |
| Market Share of Top 5 Countries | 60.8% |
Pruritus is a complex process that frequently happens with skin conditions, including atopic dermatitis and urticaria, and may harm quality of life. Additionally, it might be a sign of an underlying medical condition, such as hyperthyroidism or cholestasis, or it might just be the result of dry skin, especially during the chilly winter months.
Therapy focuses on treating the itching first, then addressing the underlying cause. Herbal therapies, prescription and over-the-counter (OTC) drugs, hydrotherapy, phototherapy, and UV therapy are all possible forms of treatment.
Key Market Highlights:
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Attributes | Details |
|---|---|
| Antipruritic Market Size (2019) | USD 9.1 billion |
| Antipruritic Market Size (2023) | USD 10.5 billion |
| Antipruritic Market CAGR (2019 to 2023) | 4.1% |
The market observed a growth of 4.1% during 2019 and 2023. The global market for antipruritic held nearly 64.6% of the overall USD 15.7 billion skin treatment market shares in 2023.
The most frequent dermatologic symptom reported by patients is pruritus. It is associated with a variety of skin conditions, the majority of which are characterized by primary lesions such as vesicles, plaques, and papules.
The underlying causes of pruritus are still unknown, making it difficult for healthcare practitioners to control itching in individuals with severe pruritus adequately. There are typically discrepancies between causative and symptomatic approaches to pruritus therapy. A common strategy for navigating the broad terrain of pruritus therapy is to categorize these alternatives according to their underlying causes.
Causative therapy aims to identify and treat the underlying illness causing the itching. Symptomatic treatment hides the itch through treatments such as cooling, heating, or counter-irritation (e.g., scratching). To provide relief sooner, symptomatic treatment and addressing the underlying disease process may be used. The popular therapeutic options are classified as symptomatic therapy and management.
Disruptive technical advancements, increasing healthcare investments, and health system optimization are driving the swift development of the medical and drug industries. Modern medical institutions, ambulatory care centers, and clinics throughout the world are deliberately adopting cutting-edge technological technologies and equipment into their operations to improve efficiency and competitiveness.
The global market's revenue growth is fuelled by factors such as rising chronic illness incidence, rapid improvements in the healthcare and medical sectors, widespread use of new instruments and techniques, and increased funding from various public and private sectors.
Furthermore, rising emphasis on drug discovery, rising need for precision medicine, widespread deployment of home care services and point-of-care diagnostics, and increased investments in R&D activities are likely to boost global market revenue and profit during the projected timeframe.
These factors are projected to impact the growth of the industry worldwide positively. With a CAGR of 4.2%, the industry is predicted to develop significantly during the following decade.
Chronic pruritus, a growing health problem, significantly impacts quality of life. Ongoing research has revealed new pathways and itch receptors, which has improved our understanding of these aspects. Expectations are strong that these latest insights are going to encourage the development of ground-breaking treatments for this frequently ignored and inconvenient ailment.
The administration of medications that reduce neural sensitization to pain, such as gabapentin, pregabalin, SSRIs, and norepinephrine antidepressants, either singly or in combination, is now required for the therapeutic management of chronic pruritus.
In the future, adopting a variety of topical and systemic medicines that focus on the different receptors and neurological pathways mediating distinct forms of itch would improve the quality of life for millions of pruritic patients.
Principal Consultant
Because of the condition's complex etiology and various contributing factors, treating chronic pruritus (CP) remains challenging. Despite the well-known antipruritic properties of traditional pharmacotherapy, such as topical therapy, light therapy, and systemic therapy, these strategies typically fail to provide significant relief for affected individuals.
Despite the wide range of therapy options, chronic pruritus is still challenging to treat. Several antipruritic treatments are still used off-label as of right now. There are currently just a few effective topical treatments for itching, and existing itch management techniques do not cover most unmet needs.
Furthermore, few published works employ general health metrics to evaluate CP, and there are very few economic statistics on the cost of chronic pruritus. According to the American Academy of Dermatology's (AAD) National Burden of Skin Disease report, pruritus-related disorders in the United States incur a yearly treatment expense of USD 294 million and an opportunity cost of USD 107 million (2017).
According to Luk et al. (2020), people with CP have an annual financial burden of USD 1,067 because of both direct and secondary medical costs. The impact of stress, anxiety, depression, and functional incapacity on the patient and their loved ones as a result of the condition are examples of what are known as intangible costs that are not taken into account by current techniques of cost assessment.
During the forecast period, the market is expected to experience barriers in its growth trajectory due to a significant financial burden, limited evidence-based data, and parameters associated with existing treatment alternatives.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 37.4% |
| China | 8.9% |
| Germany | 4.70% |
| United Kingdom | 5.10% |
| Japan | 3.20% |
The United States dominated the antipruritic market with 37.4% of market shares in 2023. The antipruritic market size in the United States is estimated to rise at a 4.30% CAGR through 2034. The country has a vast healthcare system includes comprehensive patient care and reimbursement provisions. Moreover, with greater patient awareness regarding various treatment modalities and options for pruritus treatments, the country holds a leading stance within the global market.
China captured a value share of 8.9% in the global market in 2023. The demand for antipruritic treatments is projected to surge at a 6.90% CAGR through 2034. It has been observed in several population-based studies that in Chinese patients, the frequency and severity of pruritus vary with skin conditions, skin type, age, and gender.
According to GBD 2019, young and middle-aged demographics have a higher illness burden from acne. Nearly 9.4% of the world’s population suffers from acne, making it the 8th most widespread condition globally. The market for antipruritics is driven by the increased prevalence of skin diseases in China, providing key producers with opportunities to expand within the country.
Germany held around 5.7% of the antipruritic market in 2023. The market for antipruritic in Germany is predicted to thrive at a 4.70% CAGR through 2034. In Germany, a surprisingly high number of pruritus sufferers, particularly those with specific localizations on the body, have unmet medical needs. This factor promotes opportunities for established manufacturers within the country to promote and develop novel therapeutics, addressing these unmet needs, hence propelling growth throughout the forecast period.
The United Kingdom held nearly 3.50% of the market shares in 2023. The demand for antipruritic in the United Kingdom is estimated to rise at a 5.10% CAGR through 2034. The introduction of telemedicine services in the United Kingdom has unlocked the door to online consultations and prescriptions for antipruritic drugs, increasing access to healthcare services. Government subsidies or incentives for research and development could appeal to pharmaceutical businesses to invest in producing new and improved antipruritic remedies.
Japan held nearly 5.20% of the market shares in 2023. The antipruritic market size in Japan is projected to surge at a 3.20% CAGR through 2034. Skincare and appearance are highly valued in Japanese society. A robust cultural preference for preserving good skin increases demand for antipruritic treatments, particularly those with aesthetic advantages. Japan is famous for its technological advances. Integration of cutting-edge technology, such as smart skincare devices or AI-driven diagnostic tools for dermatological diseases, could represent a differentiating element in market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segment | Immunosuppressants (Drug Type) |
|---|---|
| Value Share (2024) | 31.3% |
Immunosuppressants held a share of around 31.3% in the global market in 2023. This is due to the effectiveness of oral immunosuppressants such as cyclosporine, mycophenolate mofetil, and azathioprine in treating itching caused by inflammatory disorders like atopic dermatitis. Furthermore, systemic corticosteroids can also be administered to reduce inflammation in extreme situations of chronic pruritus.
The most effective way to reduce itching in atopic dermatitis is to manage the inflammation with topical or systemic immunosuppressive medications effectively.
| Segment | Psoriasis (Disease Type) |
|---|---|
| Value Share (2024) | 33.2% |
Psoriasis held around 33.2% of the global market in 2023. Psoriasis is a prevalent, chronic illness that has no cure. According to the 2019 report on the worldwide disease burden, there have been 4,622,594 reported cases of psoriasis globally in that year. The age range of 60 to 69 years has the maximum prevalence of psoriasis overall, with a roughly equal frequency between men and women.
The burden is substantially heavier in North American and European countries with high incomes and high SDI indices. To help reduce the disease burden of psoriasis globally, this factor fuels the interest of manufacturers in the market in the development of novel therapies.
| Segment | Oral (Route of Administration) |
|---|---|
| Value Share (2024) | 39.8% |
The oral route of administration held a share of around 39.8% in the global market in 2023. This is due to the usage of oral antihistamines for the symptomatic alleviation of pruritus. Oral antihistamines of the first or second generations, such as cetirizine and loratadine, are widely recommended. First-generation oral antihistamines include diphenhydramine and hydroxyzine.
Moreover, due to the ease of administration of oral medication dosages, the oral route of administration gains a more significant share within the global market.
| Segment | Hospital Pharmacies (Distribution Channel) |
|---|---|
| Value Share (2024) | 30.4% |
Hospital pharmacies held around 30.4% of the global market in 2023. Several institutional pharmacies provide commonly prescribed medications for pruritus at subsidized rates, thus propelling sales of antipruritics within these settings. Moreover, with the ease of dispensing, presence of branded and generic drug options, as well as greater accessibility to patients, this segment holds a dominant share within the global market.
Key players are enhancing their research and development activities to launch novel products. The expansion of their product range and efforts to improve their pipelined products are two other strategic acquisitions and partnerships with key businesses.
Recent Developments
| Attribute | Details |
|---|---|
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, the Middle East and Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, Spain, United Kingdom, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries, Turkey, North Africa, South Africa |
| Key Companies Covered | AbbVie Inc.; Allergan, Merck & Co., Inc.; Amgen Inc.; Pfizer Inc.; Cara Therapeutics; Enteris BioPharma; NeRRe Therapeutics; Menlo Therapeutics; XBiotech Inc.; Ipsen Pharma; Eledon Pharmaceuticals, Inc.; Amorepacific; RDD Pharma, Ltd; Novartis AG; AstraZeneca; Sanofi; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Cipla Ltd. |
| Key Market Segments Covered | Drug, Disease, Route of Administration, Distribution Channel, and Region |
| Pricing | Available upon Request |
The global antipruritic market is worth USD 10.9 billion in 2024.
The market is expected to reach USD 16.2 billion by the end of 2034 at a CAGR of 4.2%.
The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals.
The antipruritic market in East Asia and Latin America is expanding at 4.7% CAGR.
Europe is projected to develop with a CAGR of 4.2% during the forecast period.
The United States, the United Kingdom, China, Japan, and Germany are the top five countries in the market.
AbbVie Inc., Allergan, Merck & Co., Inc., and Pfizer Inc. are some key players in the antipruritics industry.
From 2019 to 2023, the antipruritics market expanded at a 4.1% CAGR.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug 7.1. Corticosteroids 7.2. Antihistamines 7.3. Local Anesthetics 7.4. Immunosuppressants 7.5. Others 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease 8.1. Atopic Dermatitis 8.2. Allergic Contact Dermatitis 8.3. Urticaria 8.4. Psoriasis 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration 9.1. Oral 9.2. Parenteral 9.3. Topical 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Hospital Pharmacies 10.2. Drug Stores 10.3. Retail Pharmacies 10.4. Online Stores 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. AbbVie Inc. 20.2. Allergan, Merck & Co., Inc. 20.3. Amgen Inc. 20.4. Pfizer Inc. 20.5. Cara Therapeutics 20.6. Enteris BioPharma 20.7. NeRRe Therapeutics 20.8. Menlo Therapeutics 20.9. XBiotech Inc. 20.10. Ipsen Pharma 20.11. Eledon Pharmaceuticals, Inc. 20.12. Amorepacific 20.13. RDD Pharma, Ltd 20.14. Novartis AG 20.15. AstraZeneca 20.16. Sanofi 20.17. Sun Pharmaceutical Industries Ltd. 20.18. Teva Pharmaceutical Industries Ltd. 20.19. Takeda Pharmaceutical Company Limited 20.20. Cipla Ltd. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Antipruritic Market
